微电生理(688351) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥112,652,307.04, representing a year-on-year increase of 21.78%[3] - The total profit for the period decreased by 62.44% to ¥9,281,424.74 compared to the same period last year[3] - The net profit attributable to shareholders was ¥9,252,430.88, down 62.56% year-on-year[3] - Basic earnings per share for the quarter were ¥0.0197, a decrease of 62.48% compared to the previous year[5] - Total operating revenue for the first three quarters of 2025 reached ¥336,400,837.87, an increase of 15.7% compared to ¥290,866,132.55 in the same period of 2024[23] - Net profit for the first three quarters of 2025 was ¥41,920,558.14, slightly higher than ¥41,726,652.80 in 2024, indicating a growth of 0.5%[24] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.0891, compared to ¥0.0887 in 2024, showing an increase of 0.4%[25] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥36,818,492.29, down 40.59% compared to the previous year[3] - As of September 30, 2025, the company's cash and cash equivalents amounted to RMB 437,232,111.93, an increase from RMB 269,109,754.97 as of December 31, 2024, reflecting a significant growth in liquidity[17] - The net cash flow from operating activities was $36,818,492.29, a decrease of 40.6% compared to $61,974,639.95 in the previous period[28] - The net increase in cash and cash equivalents was $168,518,040.96, contrasting with a decrease of -$23,395,248.61 in the previous period[29] - The ending balance of cash and cash equivalents was $437,232,111.93, up from $232,503,279.03 in the previous period[29] Assets and Liabilities - Total assets at the end of the period were ¥1,962,639,223.64, an increase of 3.64% from the end of the previous year[5] - Total liabilities as of the reporting date were ¥171,323,283.16, compared to ¥151,946,998.96 in the previous year, reflecting an increase of 12.7%[20] - Total assets amounted to ¥1,962,639,223.64, a slight decrease from ¥1,893,682,970.18 in the previous year[20] - Non-current liabilities totaled ¥33,610,771.08, down from ¥43,677,996.85 in the previous year, indicating a decrease of 23.0%[20] - The company reported a total equity of ¥1,791,315,940.48, an increase from ¥1,741,735,971.22 in the previous year, reflecting a growth of 2.8%[20] Research and Development - Research and development expenses totaled ¥23,663,306.79, accounting for 21.01% of operating revenue, a decrease of 2.2 percentage points from the previous year[5] - Research and development expenses for the first three quarters of 2025 were ¥45,759,833.28, down from ¥56,543,925.34 in 2024, indicating a decrease of 19.2%[24] - Development expenditures increased to ¥67,753,686.32 from ¥43,658,095.73, reflecting a focus on innovation and new product development[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,580[13] - The company reported a total of 4,728,398 shares held by China Construction Bank as part of its top shareholders, indicating strong institutional support[15] - The top ten shareholders collectively hold significant stakes, with the largest individual shareholder, Wang Ping, holding 3,591,437 shares, which represents a notable portion of the company's equity[15] - The company has not reported any changes in the status of its major shareholders or their relationships, maintaining stability in its ownership structure[16] Government Support and Financial Health - The company received government subsidies amounting to ¥2,633,436.97 during the period, contributing to the overall financial performance[7] - The company is actively monitoring its financial health and has not identified any significant risks or concerns in its operational performance during the reporting period[16]